TherapeuticsMD (TXMD) Cash & Equivalents Growth (1y) (2011 - 2026)
Powered by 
Analysis
TherapeuticsMD (TXMD) Cash & Equivalents Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 9.93% |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 1.58% |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | -14.46% |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | 14.42% |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | -40.42% |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | -30.77% |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | -57.55% |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 84.98% |
| 10 | TherapeuticsMD | 25.35 Mn | 16.16 Mn | - | 51.41% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 51.41% |
| Mar 31, 2026 | 46.54% |
| Dec 31, 2025 | 47.91% |
| Sep 30, 2025 | 40.97% |
| Jun 30, 2025 | 16.00% |
| Mar 31, 2025 | 32.43% |
| Dec 31, 2024 | 16.92% |
| Sep 30, 2024 | -50.35% |
| Jun 30, 2024 | -61.89% |
| Mar 31, 2024 | -74.85% |
| Dec 31, 2023 | -91.23% |
| Sep 30, 2023 | -73.48% |
| Jun 30, 2023 | -63.44% |
| Mar 31, 2023 | -43.23% |
| Dec 31, 2022 | -24.02% |
| Sep 30, 2022 | -63.44% |
| Jun 30, 2022 | -66.30% |
| Mar 31, 2022 | -77.92% |
| Dec 31, 2021 | -19.36% |
| Sep 30, 2021 | 31.65% |